Abacavir Sulfate

Add Info

Abacavir Sulfate Recall

Get an alert when a recall is issued.

Ask a Question

Questions & Answers

Add Info

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Add Info

Legal Issues

There is currently no legal information available for this drug.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

There is currently no usage information available for this product. We apologize for any inconvenience.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

There are no additional details available for this product.

Sources

Abacavir Sulfate Manufacturers

Mylan Pharmaceuticals Inc.

Abacavir Sulfate | Attix Pharmaceuticals

There is currently no dosage information available for this product. We apologize for any inconvenience.

No Recall
Remedyrepack Inc.

Abacavir Sulfate | Remedyrepack Inc.

A Medication Guide and Warning Card that provide information about recognition of hypersensitivity reactions should be dispensed with each new prescription and refill. Abacavir tablets may be taken with or without food.

The recommended oral dose of abacavir tablets for adults is 600 mg daily, administered as either 300 mg twice daily or 600 mg once daily, in combination with other antiretroviral agents.

The recommended oral dose of abacavir oral solution in HIV-1-infected pediatric patients aged 3 months and older is 8 mg/kg twice daily (up to a maximum of 300 mg twice daily) in combination with other antiretroviral agents.

Abacavir is also available as a scored tablet for HIV-1-infected pediatric patients weighing greater than or equal to 14 kg for whom a solid dosage form is appropriate. Before prescribing abacavir tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow abacavir tablets, the oral solution formulation should be prescribed. The recommended oral dosage of abacavir tablets for HIV-1-infected pediatric patients is presented in Table 1.
Table 1. Dosing Recommendations for Abacavir Tablets in Pediatric Patients Weight
(kg) Dosage Regimen Using Scored Tablet Total
Daily Dose AM Dose PM Dose 14 to 21 ½ tablet (150 mg) ½ tablet (150 mg) 300 mg > 21 to < 30 ½ tablet (150 mg) 1 tablet (300 mg) 450 mg ≥ 30 1 tablet (300 mg) 1 tablet (300 mg) 600 mg

The recommended dose of abacavir tablets in patients with mild hepatic impairment (Child-Pugh score 5 to 6) is 200 mg twice daily. To enable dose reduction, abacavir oral solution (10 mL twice daily) should be used for the treatment of these patients. The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate to severe hepatic impairment; therefore, abacavir tablets are contraindicated in these patients.

No Recall
Lupin Pharmaceuticals, Inc.

Abacavir Sulfate | Lupin Pharmaceuticals, Inc.

A Medication Guide and Warning Card that provide information about recognition of hypersensitivity reactions should be dispensed with each new prescription and refill. Abacavir sulfate, lamivudine and zidovudine tablets can be taken with or without food. 2.1 Adults and Adolescent Patients
The recommended oral dose of abacavir sulfate, lamivudine and zidovudine tablet is one tablet twice daily.

Abacavir sulfate, lamivudine and zidovudine tablet is not recommended in adolescents who weigh less than 40 kg because it is a fixed-dose tablet and cannot be dose adjusted.
2.2 Dosage Adjustment
Because it is a fixed-dose combination, abacavir sulfate, lamivudine and zidovudine tablets should not be prescribed for:
patients requiring dosage adjustment such as those with creatinine clearance <50 mL/min, patients with hepatic impairment.

No Recall
Mylan Institutional Inc.

Abacavir Sulfate | Mylan Institutional Inc.

• A Medication Guide and Warning Card that provide information about recognition of hypersensitivity reactions should be dispensed with each new prescription and refill. • Abacavir tablets may be taken with or without food. 2.1 Adult Patients
The recommended oral dose of abacavir tablets for adults is 600 mg daily, administered as either 300 mg twice daily or 600 mg once daily, in combination with other antiretroviral agents.
2.2 Pediatric Patients
The recommended oral dose of abacavir oral solution in HIV-1-infected pediatric patients aged 3 months and older is 8 mg/kg twice daily (up to a maximum of 300 mg twice daily) in combination with other antiretroviral agents.

Abacavir is also available as a scored tablet for HIV-1-infected pediatric patients weighing greater than or equal to 14 kg for whom a solid dosage form is appropriate. Before prescribing abacavir tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow abacavir tablets, the oral solution formulation should be prescribed. The recommended oral dosage of abacavir tablets for HIV-1-infected pediatric patients is presented in Table 1.
Table 1. Dosing Recommendations for Abacavir Tablets in Pediatric Patients
Weight
(kg)

Dosage Regimen Using Scored Tablet

Total
Daily Dose

AM Dose

PM Dose

14 to 21

½ tablet (150 mg)

½ tablet (150 mg)

300 mg

> 21 to < 30

½ tablet (150 mg)

1 tablet (300 mg)

450 mg

≥ 30

1 tablet (300 mg)

1 tablet (300 mg)

600 mg
2.3 Patients with Hepatic Impairment
The recommended dose of abacavir tablets in patients with mild hepatic impairment (Child-Pugh score 5 to 6) is 200 mg twice daily. To enable dose reduction, abacavir oral solution (10 mL twice daily) should be used for the treatment of these patients. The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate to severe hepatic impairment; therefore, abacavir tablets are contraindicated in these patients.

No Recall
State Of Florida Doh Central Pharmacy

Abacavir Sulfate | State Of Florida Doh Central Pharmacy

A Medication Guide and Warning Card that provide information about recognition of hypersensitivity reactions should be dispensed with each new prescription and refill. Abacavir tablets may be taken with or without food. 2.1 Adult Patients
The recommended oral dose of abacavir tablets for adults is 600 mg daily, administered as either 300 mg twice daily or 600 mg once daily, in combination with other antiretroviral agents.
2.2 Pediatric Patients
The recommended oral dose of abacavir oral solution in HIV-1-infected pediatric patients aged 3 months and older is 8 mg/kg twice daily (up to a maximum of 300 mg twice daily) in combination with other antiretroviral agents.

Abacavir is also available as a scored tablet for HIV-1-infected pediatric patients weighing greater than or equal to 14 kg for whom a solid dosage form is appropriate. Before prescribing abacavir tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow abacavir tablets, the oral solution formulation should be prescribed. The recommended oral dosage of abacavir tablets for HIV-1-infected pediatric patients is presented in Table 1.
Table 1. Dosing Recommendations for Abacavir Tablets in Pediatric Patients Weight
(kg) Dosage Regimen Using Scored Tablet Total
Daily Dose AM Dose PM Dose 14 to 21 ½ tablet (150 mg) ½ tablet (150 mg) 300 mg > 21 to < 30 ½ tablet (150 mg) 1 tablet (300 mg) 450 mg ≥ 30 1 tablet (300 mg) 1 tablet (300 mg) 600 mg 2.3 Patients with Hepatic Impairment
The recommended dose of abacavir tablets in patients with mild hepatic impairment (Child-Pugh score 5 to 6) is 200 mg twice daily. To enable dose reduction, abacavir oral solution (10 mL twice daily) should be used for the treatment of these patients. The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate to severe hepatic impairment; therefore, abacavir tablets are contraindicated in these patients.

No Recall
Apotex Corp

Abacavir Sulfate | Preferred Pharmaceuticals, Inc.

Dosage should be adjusted according to the severity of the pain and the response of the patient. However, it should be kept in mind that tolerance to hydrocodone can develop with continued use and that the incidence of untoward effects is dose related.
Hydrocodone Bitartrate and Acetaminophen Tablets, USP 5 mg/325 mg
The usual adult dosage is one or two tablets every four to six hours as needed for pain. The total daily dosage should not exceed 12 tablets.
Hydrocodone Bitartrate and Acetaminophen Tablets, USP 7.5 mg/325 mg
The usual adult dosage is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets.
Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/325 mg
The usual adult dosage is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets.
Hydrocodone Bitartrate and Acetaminophen Tablets, USP 5 mg/325 mg
The usual adult dosage is one or two tablets every four to six hours as needed for pain. The total daily dosage should not exceed 12 tablets.
Hydrocodone Bitartrate and Acetaminophen Tablets, USP 7.5 mg/325 mg
The usual adult dosage is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets.
Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/325 mg
The usual adult dosage is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets.

No Recall